In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Janssen Biotech teams up with Vedanta Biosciences; deal expanded; Vedanta Regains Full Rights

Executive Summary

Johnson & Johnson’s Janssen Biotech Inc. has allied with Vedanta Biosciences (focused on mucosal immunology) on the development of therapeutics that modulate pathways that interact between the human microbiome and immune system. As part of the deal, J&J's venture arm made an undisclosed equity investment in Vedanta.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register